Anti-Parkinson's disease polysaccharide PFP50-1 attenuated neuroinflammation via inhibition of TLR4/NF-κB and PI3K/Akt pathways and suppression of NLRP3 inflammasome activation

Key Points

• Polysaccharide PFP50-1 significantly attenuates neuroinflammation and TLR4/NF-κB pathway activation.
• This approach resulted in a notable decrease of NLRP3 inflammasome activation, indicating a dual pathway effect.
• Analysis using multiple cellular assays confirms the inhibition of PI3K/Akt signaling as part of the mechanism.
• Supports the possibility of complementary therapies for Parkinson's disease based on these findings.